GEXVal is a pharma spin-out drug discovery startup based in Japan.
Our mission is to Generate Extra Value to deliver cost-effective treatment to improve health and QoL of patients and families affected by rare and intractable diseases.
There are many shelved drug candidates with high potential in pharmaceutical companies that have been discontinued for strategic reasons. GEXVal identifies de-risked development programs through strategic drug repositioning research and license world-wide marketing rights of NCEs (New Chemical Entities) to reactivate program in rare diseases and engage in IND-preparation and quick-POC study in human.
GEXVal is currently seeking partners for Series B globally from APAC, Europe, and USA to accelerate first in human study for GXV-001.
Should you have any questions or interests, please contact us: email@example.com